---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-002206"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2023-02-03T23:59:59+00:00"
generated_at: "2026-06-20T01:00:12.947122+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics prices $15M public offering of common stock and warrants

## Summary
- Offering of 3.77M shares and warrants to purchase 3.77M shares at $3.98 combined price.
- Gross proceeds approx. $15M before expenses; warrants exercisable for one year at $5.00/share.
- Expected to close Feb 7, 2023; SVB Securities and RBC Capital Markets joint bookrunners.

## SEC filing metadata
- accession: 0001628280-23-002206
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2023-02-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828023002206/0001628280-23-002206-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828023002206/avtx-20230202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-002206
- JSON: https://secwatch.observer/filing/0001628280-23-002206.json
- Plain text: https://secwatch.observer/filing/0001628280-23-002206.txt

## Key facts
- Material Agreements
  Avalo Therapeutics, Inc. entered into Underwriting Agreement with SVB Securities LLC and RBC Capital Markets, LLC, as representatives of the several underwriters named therein valued at approximately $15 million (effective 2023-02-02).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: SVB Securities LLC and RBC Capital Markets, LLC, as representatives of the several underwriters named therein
  - Value: approximately $15 million
  - Effective: 2023-02-02
  source text: On February 2, 2023, Avalo Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with SVB Securities LLC and RBC Capital Markets, LLC, as representatives of the several underwriters named therein (the “Underwriters”), in connection with the public offering (the “Offering”) of an aggregate of 3,770,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share, and warrants to purchase up to an aggregate of 3,770,000 shares of common stock, at a combined price to the public of $3.98 per share and warrant, for aggregate gross proceeds of approximately $15 million, before deducting underwriting discounts and commissions and estimated fees and expenses payable by the Company in connection with the Offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828023002206/0001628280-23-002206-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.